S&P 500 Futures
(-0.08%) 5 304.25 points
Dow J Futures
(-0.09%) 40 140 points
Nasdaq Futures
(-0.05%) 18 465 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(0.21%) $923.00
USD/EUR
(0.21%) $0.928
USD/NOK
(0.14%) $10.86
USD/GBP
(-0.03%) $0.792
USD/RUB
(-0.34%) $92.26

Realtime updates for Cellectis S.A. [CLLS]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Last Updated28 Mar 2024 @ 16:00

-0.75% $ 2.65

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 16:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302
Profile picture for Cellectis S.A.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells...

Stats
Today's Volume 44 042.00
Average Volume 44 057.00
Market Cap 190.14M
EPS $0 ( 2024-03-27 )
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -1.880
ATR14 $0.0200 (0.75%)

Cellectis S.A. Correlation

10 Most Positive Correlations
AXTI0.876
ABCL0.873
BNIXU0.868
BCOV0.867
PASG0.865
SAFT0.862
SVOK0.861
ATNI0.861
EQ0.855
GTEC0.854
10 Most Negative Correlations
ASLN-0.852
RDI-0.829
LNTH-0.826
NOVV-0.82
ORTX-0.816
TIG-0.816
PPYAU-0.813
LUNG-0.809
BRIVU-0.802
LINK-0.801

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cellectis S.A. Financials

Annual 2022
Revenue: $19.17M
Gross Profit: $17.40M (90.76 %)
EPS: $-2.17
Q3 2023
Revenue: $155 000
Gross Profit: $-26 000.00 (-16.77 %)
EPS: $-0.310
Q2 2023
Revenue: $178 000
Gross Profit: $123 000 (69.10 %)
EPS: $-0.190
Q1 2023
Revenue: $139 000
Gross Profit: $-195 000 (-140.29 %)
EPS: $-0.580

Financial Reports:

No articles found.

Cellectis S.A.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators